539730 — Fredun Pharmaceuticals Share Price
Last trade - 00:00- IN₹12.74bn
- IN₹13.96bn
- IN₹6.35bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.58 | ||
| Price to Tang. Book | 4.59 | ||
| Price to Free Cashflow | 30.57 | ||
| Price to Sales | 2 | ||
| EV to EBITDA | 15.27 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 24.11% | ||
| Return on Equity | 15.83% | ||
| Operating Margin | 13.1% | ||
Financial Summary
| Year End 31st Mar | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 2,217.37 | 2,743.42 | 3,465.77 | 4,538.18 | 6,354.66 | n/a | n/a | 37.02% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +106.73 | +61.99 | +44.23 | +28.44 | +45.98 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Fredun Pharmaceuticals Ltd. is an India-based pharmaceuticals formulation manufacturing company. The Company is engaged in manufacturing dietary/herbal supplements, nutraceuticals, and other healthcare products, along with animal healthcare products. Its segment includes Fredun Generics, Pet Care, Nutraceuticals, Cosmeceuticals and Mobility. Its Generics Division, marketed under the Fredun Gx brand. The Pet Healthcare segment operates under the Freossi brand. The Nutraceutical Division under Fredun Nutrition brand. Its Cosmeceuticals Division, operating under the Bird N Beauty (BNB) and Beautyfred brands, is focused on skincare and personal care products. Its Mobility Division, operating under Chuu Balm, BraceOn, NebOn, and DigiOn, caters to the ortho rehabilitation aids and pain management market. It offers a range of products, including antihypertensive, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It also provides comprehensive pet care technology platforms.
Directors
- Daulat Medhora CHM (76)
- Fredun Medhora CFO (34)
- Jinkal Shah CCO
- Narman Medhora EDR
- Rohinton Kanga NID
- Aspi Raimalwala NID
- Chandrakant Shah NID
- Last Annual
- March 31st, 2026
- Last Interim
- March 31st, 2026
- Incorporated
- June 8th, 1987
- Public Since
- March 17th, 2016
- No. of Employees
- 736
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Bombay Stock Exchange
- Shares in Issue
- 5,512,690
- Address
- 26 Manoj Industrial Premises, MUMBAI, 400013
- Web
- http://www.fredungroup.com/pharmaceutical.html
- Phone
- +91 2240318111
- Contact
- Fredun Medhora
- Auditors
- RH NISAR & CO
Latest News for 539730
Upcoming Events for 539730
Dividend For FRED.BO - 0.7000 INR
Q1 2027 Fredun Pharmaceuticals Ltd Earnings Release
Fredun Pharmaceuticals Ltd Annual Shareholders Meeting
Q2 2027 Fredun Pharmaceuticals Ltd Earnings Release
Similar to 539730
Aayush Wellness
Bombay Stock Exchange
Accretion Nutraveda
Bombay Stock Exchange
Achyut Healthcare
Bombay Stock Exchange
Adline Chem Lab
Bombay Stock Exchange
MPS Pharmaa
Bombay Stock Exchange
FAQ
As of Today at 02:43 UTC, shares in Fredun Pharmaceuticals are trading at IN₹2,310.75. This share price information is delayed by 15 minutes.
Shares in Fredun Pharmaceuticals last closed at IN₹2,310.75 and the price had moved by +189.06% over the past 365 days. In terms of relative price strength the Fredun Pharmaceuticals share price has outperformed the S&P BSE 100 Index by +200.81% over the past year.
There is no consensus recommendation for this security.
Find out moreThe Fredun Pharmaceuticals dividend yield is 0.03% based on the trailing twelve month period.
Last year, Fredun Pharmaceuticals paid a total dividend of IN₹0.70, and it currently has a trailing dividend yield of 0.03%.Looking ahead, shares in Fredun Pharmaceuticals are due to go ex-dividend on 2026-06-23 and the next dividend pay date is 2026-07-30.
Fredun Pharmaceuticals are due to go ex-dividend on 2026-06-23 and the next dividend pay date is 2026-07-30. The historic dividend yield on Fredun Pharmaceuticals shares is currently 0.03%.
To buy shares in Fredun Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹2,310.75, shares in Fredun Pharmaceuticals had a market capitalisation of IN₹12.74bn.
Here are the trading details for Fredun Pharmaceuticals:
- Country of listing: India
- Exchange: BSE
- Ticker Symbol: 539730
Based on an overall assessment of its quality, value and momentum Fredun Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fredun Pharmaceuticals. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +58.65%.
As of the last closing price of IN₹2,310.75, shares in Fredun Pharmaceuticals were trading +34.36% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Fredun Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹2,310.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Fredun Pharmaceuticals' management team is headed by:
- Daulat Medhora - CHM
- Fredun Medhora - CFO
- Jinkal Shah - CCO
- Narman Medhora - EDR
- Rohinton Kanga - NID
- Aspi Raimalwala - NID
- Chandrakant Shah - NID